Kazerani, Maryam http://orcid.org/0000-0002-5803-4807
Marcinek, Anetta
Philipp, Nora http://orcid.org/0000-0002-3918-7795
Brauchle, Bettina
Taylor, Jonathan Jonas
Moreno, Helena Domínguez
Terrasi, Andrea
Tast, Benjamin
Rohrbacher, Lisa
Wang, Yingshuai
Warm, Maximilian
Emhardt, Alica-Joana
Magno, Giulia
Spiekermann, Karsten http://orcid.org/0000-0002-5139-4957
Herold, Tobias http://orcid.org/0000-0002-9615-9432
Straub, Tobias
Theurich, Sebastian http://orcid.org/0000-0001-5706-8258
Schotta, Gunnar http://orcid.org/0000-0003-4940-6135
Kischel, Roman
Bücklein, Veit L. http://orcid.org/0000-0001-7391-7280
Subklewe, Marion http://orcid.org/0000-0001-9154-9469
Article History
Received: 13 March 2024
Revised: 5 August 2024
Accepted: 14 August 2024
First Online: 22 August 2024
Competing interests
: MS has received industry research support from Amgen, BMS/Celgene, Gilead/Kite, Miltenyi Biotec, Molecular Partners, Morphosys, Novartis, Roche, Seattle Genetics, and Takeda, and has served as a consultant/scientific advisory board member at Autolus, AvenCell, CanCell Therapeutics, CDR-Life, Genmab US, Ichnos Sciences, Incyte Biosciences, Interius BioTherapeutics, Janssen, Millennium Pharmaceuticals, Miltenyi Biomedicine, Molecular Partners, Nektar Therapeutics, Novartis, Pfizer, Ridgeline Discovery, Sanofi, Scare, and Takeda. She serves on the speakers’ bureau at Amgen, AstraZeneca, BMS/Celgene, Gilead/Kite, GSK, Janssen, Novartis, Octapharma, Pfizer, Roche, Springer Healthcare, and Takeda. Educational grants were received to develop the app “MyTcell” from BMS, Gilead, Janssen, Novartis, Roche, and Takeda. VLB has received research funding from BMS, Gilead/Kite, Miltenyi Biotec, Novartis, and Roche, and has served as a consultant/advisor to Amgen, Gilead, Novartis, Pfizer, and Priothera. He serves on the speakers’ bureau at Novartis and Pfizer. RK is employed at Amgen Research Munich, Germany. ST has served as a consultant/advisor to Amgen, BMS, GSK, Janssen, Pfizer, Sanofi, and Takeda. TH has received industry research support from Roche and served as a scientific advisory board member to Servier. MK, AM (now employed by MLL Munich Leukemia Laboratory), NP, BB (now employed by Adivo), JJT (now employed by AstraZeneca), HDM (now employed by MundiCare), AT, BT, LR, YW, MW, A-JE, GM, KS, TS, and GS declare no relevant conflicts of interest. Correspondence: Marion Subklewe, Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; e-mail: marion.subklewe@med.uni-muenchen.de.